SEATTLE, Oct. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq; MTAX: CTIC) announced today that it received the required antitrust regulatory clearance for and has closed on the Securities Purchase Agreement announced on September 18, 2006 between CTI and Novartis Pharma AG. In addition, the License and Co-Development between CTI and Novartis International Pharmaceutical Ltd. previously announced on September 18, 2006 became effective upon receipt of the required antitrust regulatory clearance.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com/.
